AR and benign prostatic hyperplasia: Given the shared involvement of androgen receptor signaling and 5α-reductase activity in both prostate cancer and BPH (Andriole et al., 2004; Nacusi and Tindall, 2011), we evaluated nobiletin as a candidate for BPH.